跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SAPHNELO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SAPHNELO
Authorized
STANDARD
SAPHNELO
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ad84df800dc83fd4
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
ad84df800dc83fd4
Drug Approval Canada Name
SAPHNELO
Product Name
SAPHNELO
Status
Marketed
Status Date
2022-03-01
Original Market Date
2022-03-01
Din
02522845
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
90:24.28
Atc Original
L04AG11 ANIFROLUMAB
Atc Name
l 04 ag 11
Aig Number
0163278001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
ANIFROLUMAB
150 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ad84df800dc83fd4
Type
Standard
Back to Health Canada Approvals